Filing Analysis
Material Agreement
Filed Apr 07, 2026
MEDIUM
GT Biopharma entered into a $3.8 million Investigator Initiated Clinical Trial Agreement with the University of Minnesota to conduct a Phase 1a/1b clinical trial for its GTB-5550 drug candidate. The University will sponsor the IND application and lead the research program targeting advanced solid tumors over a three-year period.
Red Flags
- The Company transitioned to a fully remote model as of July 1, 2024, and does not maintain a principal executive office.
- The University has the right to terminate the agreement immediately for health, welfare, and safety reasons.
Key Facts
- Agreement signed on April 3, 2026, with the Regents of the University of Minnesota.
- The study focuses on GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®).
- The Company is committed to a budget of approximately $3.8 million over three years.
- The University will sponsor the Investigational New Drug (IND) application (IND 169118).
- The trial is a Phase 1a/1b study for advanced solid tumors that have failed prior therapy.
Financial Restatement
Filed Mar 02, 2026
HIGH
GT Biopharma is restating its financial statements for the second and third quarters of 2025 due to the misclassification of stock purchase rights ('Greenshoe Rights') as equity instead of liabilities. The correction results in a massive non-cash increase in net loss for the first half of 2025, though it does not impact the company's cash position.
Red Flags
- Material restatement of previously issued financial statements (Item 4.02).
- Significant accounting error involving complex financial instruments (ASC 480 compliance).
- Massive adjustment to net loss ($28.7M) relative to total assets ($7.1M).
- Accumulated deficit reached $718.1 million as of September 30, 2025.
Key Facts
- The restatement affects Quarterly Reports on Form 10-Q for the periods ended June 30, 2025, and September 30, 2025.
- The error relates to Series L 10% Convertible Preferred Stock purchase rights issued in May 2025 which required liability classification under ASC 480.
- For the three months ended June 30, 2025, net loss was adjusted from $1.4 million to $30.2 million, a $28.7 million increase.
- Net loss per share for the six months ended June 30, 2025, was restated from $0.90 to $12.12.
- The company became fully remote as of July 1, 2024, and no longer maintains a principal executive office.
- The Greenshoe Rights liability was extinguished and reclassified to equity in September 2025 after a redemption rights waiver.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.